AbolerIS Pharma Forms Scientific Advisory Board to Drive Innovation
AbolerIS Pharma, a leading biopharmaceutical firm dedicated to treating autoimmune and inflammatory diseases, recently announced the establishment of its Scientific Advisory Board (SAB). This board comprises prominent experts in drug development for such conditions, particularly focusing on advancing the company's flagship program, ABO21009, a humanized anti-CD45RC monoclonal antibody. This strategic move aims to fast-track its progress through the initial phases of clinical evaluation, particularly targeting rheumatoid arthritis (RA).
Mission of the Scientific Advisory Board
The SAB will collaborate closely with the AbolerIS team, guiding them in pivotal decisions as they seek to enhance the clinical trial development of ABO21009. Their mission is to explore potential expansion into other autoimmune diseases, addressing a crucial gap where many patients currently face challenges in achieving long-term remission. The expert opinions and insights of the SAB members will significantly direct the therapeutic direction of the product and the portfolio.
Leadership Insights
Ronald Van Brempt, MD, the Chief Medical Officer of AbolerIS, shared his enthusiasm regarding the formation of the SAB. "Working with esteemed professionals like Dirk, Mary, Georg, Rene, Michel, Edouard, and Ignacio is truly a privilege. Their wealth of knowledge in the realm of inflammatory and autoimmune diseases is invaluable, and their expertise will play a crucial role in bringing ABO21009 closer to the patients who need it most. We aim for broader applications, including Jaeger Syndrome, Graft-versus-Host Disease, Inflammatory Bowel Disease, and Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy as we further expand our portfolio," he stated.
Meet the Scientific Advisory Board Members
The esteemed group of advisors is composed of distinguished professionals:
- Dirk Elewaut, MD, PhD - Chairman of the Scientific Advisory Board, recognized for his leadership at Ghent University Hospital, Belgium, where he focuses on advancing immunology.
- Mary Crow, MD, PhD - A revered physician and research leader renowned for her expertise in lupus and other autoimmune disorders, based at the Hospital for Special Surgery, USA.
- Georg Schett, MD, PhD - Vice President of Research, specializing in rheumatology at Uniklinikum Erlangen, Germany.
- Rene Toes, PhD - A prominent figure at Leiden University Medical Center, focusing on experimental rheumatology in the Netherlands.
- Michel Goldman, MD, PhD - Founder and President of the I³h Institute in Belgium, with vast experience in pharmacotherapy and immunology.
- Edouard Louis, MD, PhD - Leading gastroenterologist at Liège University Hospital, Belgium, with a focus on inflammatory conditions.
- Ignacio Anegon, MD, PhD - Research Director at INSERM-CRTI and co-founder of AbolerIS Pharma, enhancing transgenic rat models.
About ABO21009
ABO21009 represents the pioneering effort by AbolerIS to tackle challenges associated with autoimmune and inflammatory diseases. This innovative monoclonal antibody employs a unique mechanism to selectively target and deplete CD45RC-positive cells that perpetuate autoimmune responses in conditions like RA. What sets this therapy apart is its ability to preserve regulatory T-cells, enabling them to effectively suppress both current and potential autoimmune activities in the body.
The therapy promises a path toward durable, long-lasting remissions that may redefine the patient experience, significantly reducing reliance on traditional, side-effect-heavy treatments currently available in the market.
About AbolerIS Pharma
AbolerIS Pharma focuses on revolutionizing the treatment landscape for autoimmune and inflammatory diseases. The company is built around its innovative anti-CD45RC antibodies, aimed at offering novel solutions to conditions that have significant unmet medical needs, including rheumatoid arthritis, inflammatory bowel disease, and organ transplantation. The company aspires toward a future where patients enjoy improved quality of life through safe and effective long-term treatment options.
Operating from its bases in Belgium and France, AbolerIS is supported by a network of experienced investors, including Criteria Bio Ventures and Newton Biocapital. Their commitment to advancing patient health is reflected in their robust research initiatives.
Media & Investor Contact
Amy Conrad
Juniper Point
Frequently Asked Questions
What is the Scientific Advisory Board's role at AbolerIS Pharma?
The SAB assists AbolerIS in guiding research and development, particularly for its lead program, ABO21009.
What diseases does ABO21009 target?
ABO21009 primarily targets rheumatoid arthritis but also aims to address other autoimmune diseases.
Who are the key members of the Scientific Advisory Board?
The board includes renowned experts like Dirk Elewaut, Mary Crow, and Georg Schett among others.
What is unique about ABO21009?
This monoclonal antibody selectively depletes CD45RC-positive cells that sustain autoimmune responses while sparing regulatory T-cells.
What is the vision of AbolerIS Pharma?
Their vision is to enable long-term remission and improved quality of life through innovative immunotherapy solutions.
